吡柔比星与丝裂霉素C膀胱内灌注预防浅表性膀胱癌术后复发的疗效比较  

Effects of bladder perfusion with mitomycin and pirarubicin on preventing recurrence of superficial bladder cancer

作　　者：林豪胜 吴保忠[1] 杨帝宽 刘明建[1] 张启飞[1] 

机构地区：[1]广东省肇庆市第二人民医院泌尿外科,526060

出　　处：《中国实用医药》2013年第16期59-60,共2页China Practical Medicine

摘　　要：目的探讨分析膀胱内灌注吡柔比星(THP)与丝裂霉素C(MMC)在预防浅表性膀胱癌术后复发上的疗效。方法随机选择2006年～2010年在本院泌尿外科手术治疗的140例浅表性膀胱癌患者,按照随机对照的原则分为吡柔比星组(TH组,n=70)及丝裂霉素组(MMC组,n=70),分别进行膀胱内灌注化疗,随访2年,观察肿瘤术后复发情况。结果丝裂霉素组患者的复发率高于吡柔比星,差异有统计学意义(P<0.05)。结论吡柔比星的疗效优于丝裂霉素,副作用较少。Objective To observed the different curative effect of bladder perfusion with mitomycin and pirarubicin on preventing recurrence of superficial bladder cancer after the patients treated with TUR-Bt. Methods 140 cases superficial bladder cancer after operation were randomly devided into two groups, using mitomycin and pirarubicin respectively as perfusion drug. Results All patients were followed up for two years. The recurrence rate in pirarubicin group was lower than that in mitomycin group. Conclusion The effect of pirarubicin perfusion was better than mitomycin, and adverse reaction were little. It was worthy for more wide spread.

关 键 词：膀胱癌 吡柔比星 丝裂霉素 膀胱内灌注 复发 

分 类 号：R737.14[医药卫生—肿瘤]